A5050781816- Statistical Methods in Clinical Trials
- Diabetes Treatment and Management
- Pancreatitis Pathology and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Causal Inference Techniques
- Streptococcal Infections and Treatments
- Pancreatic function and diabetes
- Infective Endocarditis Diagnosis and Management
- Global Cancer Incidence and Screening
- Cardiac Valve Diseases and Treatments
- Autoimmune and Inflammatory Disorders Research
- Multiple Sclerosis Research Studies
- COVID-19 epidemiological studies
- Firm Innovation and Growth
- Biosimilars and Bioanalytical Methods
- Spectroscopy Techniques in Biomedical and Chemical Research
- Systemic Sclerosis and Related Diseases
- Hate Speech and Cyberbullying Detection
- SARS-CoV-2 and COVID-19 Research
- Occupational and environmental lung diseases
- Neuroendocrine Tumor Research Advances
- Merger and Competition Analysis
- Pharmaceutical studies and practices
- BRCA gene mutations in cancer
- Data-Driven Disease Surveillance
Bristol-Myers Squibb (United States)
2023-2024
AstraZeneca (United States)
2020-2023
The George Institute for Global Health
2022
AstraZeneca (Sweden)
2021
United States Food and Drug Administration
2008
Yale University
1999-2003
Context Complicated left-sided native valve endocarditis causes significant morbidity and mortality in adults. Lack of valid data regarding estimation prognosis makes management this condition difficult. Objective To derive externally validate a prognostic classification system for adults with complicated endocarditis. Design, Setting, Patients Retrospective observational cohort study conducted from January 1990 to 2000 at 7 Connecticut hospitals among 513 patients older than 16 years who...
Complicated, left-sided native valve endocarditis causes significant morbidity and mortality in adults. The presumed benefits of surgery remain unproven due to lack randomized controlled trials.To determine whether is associated with reduced adults complicated, endocarditis.Retrospective, observational cohort study conducted from January 1990 2000 at 7 Connecticut hospitals. Propensity analyses were used control for bias treatment assignment prognostic imbalances.Of the 513 endocarditis, 230...
From 1982 to 1984, the authors conducted a population-based case-control study of lung cancer in men and women nonsmokers New York State. In-person interviews were completed for 437 cases (197 never smokers, 240 former smokers) matched population controls. Cases controls asked report any history physician-diagnosed nonmalignant disease; more likely than such history. Statistically significant associations found emphysema (odds ratio (OR) = 1.94, 95% confidence interval (CI) 1.10–3.43),...
Abstract Aims Coronavirus disease 2019 (COVID‐19) is caused by a novel severe acute respiratory syndrome coronavirus 2. It can lead to multiorgan failure, including and cardiovascular decompensation, kidney injury, with significant associated morbidity mortality, particularly in patients underlying metabolic, cardiovascular, or disease. Dapagliflozin, sodium‐glucose cotransporter‐2 inhibitor, has shown cardio‐ renoprotective benefits type 2 diabetes (with without atherosclerotic disease),...
The win ratio is a general method of comparing locations distributions two independent, ordinal random variables, and it can be estimated without distributional assumptions. In this paper we provide unified theory estimation in the presence stratification adjustment by numeric variable. Building step on estimate crude compare corresponding tests with well known nonparametric group difference (Wilcoxon rank-sum test, Fligner-Plicello Cochran-Mantel-Haenszel test based regression ranks rank...
The win odds is a distribution-free method of comparing locations distributions two independent random variables. Introduced as for analyzing hierarchical composite endpoints, it well suited to be used in the analysis ordinal scale endpoints COVID-19 clinical trials. For single outcome, we provide power and sample size calculation formulas test. We also an implementation outcome commonly statistical software make fully reproducible.
Patients who were hospitalized with coronavirus disease 2019 (COVID-19) infection are at high risk of AKI and KRT, especially in the presence CKD. The Dapagliflozin Respiratory Failure COVID-19 (DARE-19) trial showed that patients COVID-19, treatment dapagliflozin versus placebo resulted numerically fewer participants experienced organ failure or death, although these differences not statistically significant. We performed a secondary analysis DARE-19 to determine efficacy safety on kidney...
The COVID-19 pandemic presents unprecedented challenges for drug developers seeking to evaluate the safety and efficacy of potential treatments COVID-19. Clinical researchers must work quickly adapt emerging data. Building upon FDA guidance document Duke-Margolis' critical path rapid development access safe effective therapeutics, this article focuses on statistical opportunities nimble accelerated therapeutics. We focus acceleration by way increasing clinical trial efficiency, facilitating...
Abstract A model‐based approach to analyze two incomplete disease surveillance datasets is described. Such data typically consist of case counts, each originating from a specific geographical area. Bayesian hierarchical model proposed for estimating the total number cases with while simultaneously adjusting spatial variation. This explicitly accounts uncertainty and can make use covariates. The method applied maintained by Centers Disease Control Prevention on Rocky Mountain spotted fever...